Merck & Co gets in on the bispecific act
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
